Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines by Manoj B. Parmar et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIOENGINEERING AND BIOTECHNOLOGY
ORIGINAL RESEARCH ARTICLE
published: 16 February 2015
doi: 10.3389/fbioe.2015.00014
Targeting cell cycle proteins in breast cancer cells with
siRNA by using lipid-substituted polyethylenimines
Manoj B. Parmar 1, Hamidreza Montazeri Aliabadi 2,3, Parvin Mahdipoor 2, Cezary Kucharski 2,
Robert Maranchuk 4, Judith C. Hugh5 and Hasan Uludag˘1,2,6*
1 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
2 Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB, Canada
3 School of Pharmacy, Chapman University, Irvine, CA, USA
4 Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
5 Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
6 Department of Biomedical Engineering, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
Edited by:
Malcolm Xing, University of
Manitoba, Canada
Reviewed by:
Stephanie Michelle Willerth,
University of Victoria, Canada
Wen Zhong, University of Manitoba,
Canada
*Correspondence:
Hasan Uludag˘, Department of
Chemical and Materials Engineering,
University of Alberta, Edmonton,
Alberta, T6G 2G6, Canada
e-mail: hasan.uludag@ualberta.ca
The cell cycle proteins are key regulators of cell cycle progression whose deregulation is
one of the causes of breast cancer. RNA interference (RNAi) is an endogenous mecha-
nism to regulate gene expression and it could serve as the basis of regulating aberrant
proteins including cell cycle proteins. Since the delivery of small interfering RNA (siRNA)
is a main barrier for implementation of RNAi therapy, we explored the potential of a non-
viral delivery system, 2.0 kDa polyethylenimines substituted with linoleic acid and caprylic
acid, for this purpose. Using a library of siRNAs against cell cycle proteins, we identified
cell division cycle protein 20 (CDC20), a recombinase RAD51, and serine–threonine pro-
tein kinase CHEK1 as effective targets for breast cancer therapy, and demonstrated their
therapeutic potential in breast cancer MDA-MB-435, MDA-MB-231, and MCF7 cells with
respect to another well-studied cell cycle protein, kinesin spindle protein. We also explored
the efficacy of dicer-substrate siRNA (DsiRNA) against CDC20, RAD51, and CHEK1, where
a particular DsiRNA against CDC20 showed an exceptionally high inhibition of cell growth
in vitro.There was no apparent effect of silencing selected cell cycle proteins on the potency
of the chemotherapy drug doxorubicin. The efficacy of DsiRNA against CDC20 was sub-
sequently assessed in a xenograft model, which indicated a reduced tumor growth as a
result of CDC20 DsiRNA therapy. The presented study highlighted specific cell cycle pro-
tein targets critical for breast cancer therapy, and provided a polymeric delivery system for
their effective down-regulation.
Keywords: breast cancer therapy, cell cycle protein, DsiRNA, CDC20, RAD51, CHEK1, lipid-substituted polymers,
non-viral siRNA delivery, Xenograft, siRNA therapy
INTRODUCTION
There are significant limitations and side-effects to conventional
chemotherapy employed in management of breast cancer. Malig-
nant cells can additionally develop resistance to chemotherapy
by changing their molecular (genetic) makeup (Luqmani, 2005;
Gillet and Gottesman, 2010). The development of drug resistance
in particular warrants a search for alternative and more effective
therapies in breast cancer. The treatment of cancer based on RNA
interference (RNAi) using small interfering RNA (siRNA) has been
a promising approach and it is actively explored as an alterna-
tive to chemotherapy (McManus and Sharp, 2002; Kim and Rossi,
2007). Double-stranded synthetic siRNA can be incorporated into
the RNA inducing silencing complex (RISC) following the release
of the passenger strand and leaving the guide strand of siRNA
bound to RISC (Kim and Rossi, 2007; Wilson and Doudna, 2013).
The guide strand directs the siRNA–RISC complex to a targeted
mRNA. The siRNA–RISC complex can bind and either cleave the
target mRNA via endonuclease activity or block the translation
of mRNA, resulting in the “silencing” of a specific target (Wilson
and Doudna, 2013). However, the binding of siRNA on its own to
cell membranes and subsequent uptake is nearly impossible due
to its highly anionic nature (Pecot et al., 2011; Bora et al., 2012).
The naked siRNA is, moreover, instantly degraded by RNase A in
extracellular milieu, resulting in a poor pharmacokinetics profile
(Haupenthal et al., 2006). Well-designed carriers are, therefore,
necessary to neutralize the anionic charge of siRNA to facilitate
its intracellular delivery and inhibit extracellular degradation. We
reported a library of cationic polymers based on low molecular
weight (2 kDa) polyethylenimine (PEI) that are substituted with
different hydrophobic moieties and have shown effective transfec-
tion efficiency without significant toxicity (Aliabadi et al., 2011,
2013a,b; Montazeri Aliabadi et al., 2011). Cationic PEI binds to
siRNA to provide effective protection against enzymatic degrada-
tion, and delivers siRNA into the cells for assembly into the RISC
(Aliabadi et al., 2012).
The cell cycle constitutes a series of events that leads to con-
trolled cell division and multiplication (Cooper, 2000). Since
deregulation of cell cycle events leads to uncontrolled cell prolif-
eration and is a hallmark of malignancy (Sandhu and Slingerland,
2000; Malumbres and Carnero, 2003), the molecular mediators
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responsible for abnormal cell cycle regulation are viable targets
for siRNA therapy. There are several factors that can deregulate a
cell cycle; mutation of a regulatory protein might lead to a loss of
binding to its target, or overexpression of a critical protein might
lead to constitutive activation of cell cycle. In such cases, malignant
cells could proliferate at faster rate than the normal cells, and/or
lose the efficiency to detect DNA damage and arrest the progres-
sion of cell cycle (Sandhu and Slingerland, 2000; Malumbres and
Carnero, 2003). Overexpressed or mutated cell cycle proteins can,
therefore, be targeted as the basis of a breast cancer therapy. Many
proteins have been found de-regulated during the progression of
cell cycle such as the cyclins and cyclin dependent kinases (CDKs)
(Vermeulen et al., 2003; Parmar and Uludag˘, 2015), and some
efforts have been directed to regulate the uncontrolled malignant
cell proliferation by delivering siRNA specific to such proteins.
To explore the role of cell cycle proteins as the basis of a breast
cancer therapy, this study has undertaken a general approach
to identify therapeutically useful targets with polymer-mediated
siRNA delivery. Several in-house prepared lipophilic PEIs and a
library of siRNAs against cell cycle proteins were screened for
this purpose in breast cancer cells. Kinesin spindle protein (KSP),
which is required to form a bipolar spindle in mitosis by separat-
ing the emerging spindle poles (Blangy et al., 1995; Dagenbach and
Endow, 2004), was employed as a reference target since an siRNA
against KSP is at early stages of clinical trials (Marra et al., 2013;
Tabernero et al., 2013). We hypothesized that silencing critical cell
cycle proteins by RNAi would result in reduced cell growth and
decreased viability of malignant cells. We further hypothesize that
polymeric delivery of siRNA is an effective approach to silence cell
cycle proteins in breast cancer cells. The objectives of this study
were to find the optimal siRNA delivery system and to identify
most effective cell cycle protein target(s) for therapeutic silencing
in breast cancer cells. Moreover, we explored the efficacy of siRNA
and dicer-substrate siRNA (DsiRNA) in vitro and in vivo. Unlike
the conventional 21-bp double-stranded siRNA, longer DsiRNA
can incorporate into the Dicer enzyme in RISC complex, leading
to improved silencing efficacies (Amarzguioui and Rossi, 2008).
MATERIALS AND METHODS
CELL-LINES
The wild-type (WT) and drug-resistant (R) breast cancer MDA-
MB-435 cells were cultured in RPMI 1640 medium, while MDA-
MB-231 (WT and R phenotypes) and MCF7 breast cancer cells
were cultured in DMEM medium with 10% FBS, 100 U/mL peni-
cillin, and 100µg/mL streptomycin, and maintained at 37°C and
5% CO2. The drug resistance in MDA-MB-435 and MDA-MB-
231 cells was developed as described in Aliabadi et al. (2013a,b),
and was confirmed periodically by evaluating the IC50 (i.e.,
concentration for 50% cell kill) of doxorubicin in both cell-lines.
POLYMERIC CARRIERS AND siRNA–POLYMER COMPLEX PREPARATION
Polyethylenimines (2 kDa branched) modified with linoleic acid
(LA, 1.65 substitutions/PEI), caprylic acid (CA, 6.0 substitu-
tions/PEI), and α-linoleic acid (αLA, 0.5 substitutions/PEI) were
synthesized according to our established protocol (Bahadur et al.,
2011; Remant Bahadur and Uludag˘, 2011) and the degree of
substitution was determined by 1H-NMR. The siRNA–polymer
complexes were prepared in 150 mM NaCl, and were added to
the cells after 30 min of incubation. The siRNA:polymer ratio
in the complexes were either 1:2, 1:4, or 1:8 (w/w), and com-
plexes were added to the cells at desired siRNA concentrations
(see Figure legends for exact ratios and concentrations). The
lipid-based commercial carriers, HiperFect (Qiagen, Valencia, CA,
USA), and TurboFect (Thermo Fisher Scientific, Waltham, MA,
USA) were included in the screening with the synthesized poly-
mers, and they were used to make complexes as suggested by the
manufacturers.
CELLULAR UPTAKE OF siRNA BY FLOW CYTOMETRY AND CONFOCAL
MICROSCOPY
To investigate quantitative uptake of siRNA, MDA-MB-435WT
were seeded in 24-well plates, and transfected with 6-
carboxyfluorescein (FAM)-labeled scrambled siRNA (Cat. No.
AM4620; Life Technologies) at 20 and 40 nM concentrations with
1:2, 1:4, and 1:8 siRNA:PEI–LA ratios. Non-labeled scrambled
siRNA was used as a negative control. After 24 h of treatment,
cells were washed with Hank’s Balanced Salt Solution (HBSS),
treated with trypsin/Ethylenediaminetetraacetic acid (EDTA), and
the recovered cells were fixed with 3.7% formaldehyde. The uptake
of siRNA was quantified using Cell Lab Quanta SC flow cytome-
ter (Beckman Coulter, Brea, CA, USA). The mean fluorescence of
the recovered cell population and the percentage of cells showing
FAM-fluorescence were determined. Gating of the cell popula-
tion was such that auto-fluorescence of untreated cells represented
1–2% of the total cell population.
To further investigate qualitative uptake of siRNA, MDA-MB-
435WT were grown on glass cover slips (Thermo Fisher Scientific)
for 24 h and transfected by non-labeled scrambled siRNA and
FAM-labeled scrambled siRNA complexes at 40 nM with 1:2 and
1:8 siRNA to PEI–LA ratios. After 24 h, cells were washed with
HBSS, fixed with 3.7% formaldehyde and mounted on a slide using
in-house prepared mounting medium (poly vinyl alcohol in glyc-
erol) with 4′,6-diamidino-2-phenylindole (DAPI, Life Technolo-
gies) to stain nuclei and wheat germ agglutinin, tetramethylrho-
damine conjugate (Invitrogen) to stain cytoplasmic membrane.
Prepared slides were studied using 40× 1.3 oil plan-Apochromat
lens in Laser Scanning Confocal Microscope (LSM710, Carl Zeiss
AG, Oberkochen, Germany), and using ZEN 2011 software. The
number of siRNA–polymer complexes per cell was determined by
Imaris software (Bitplane, Belfast, UK). The similar uptake study
was performed using MCF7 cells (Figure S1 in Supplementary
Material).
SCREENING OF CELL CYCLE PROTEINS
The human siGENOME siRNA Library on Cell Cycle Regulation
(Dharmacon, Lafayette, CO, USA) was used to screen 169 siR-
NAs to determine the potential cell cycle proteins that can be
used as siRNA targets in breast cancer cells. The siRNAs were
formulated as a mixture of four different sequences in the library
targeting specific protein at four different sites. MDA-MB-435R
and MDA-MB-231R cells were cultured in 96-well plate and
transfected with 54 nM of each cell cycle protein siRNA at 1:4
siRNA:PEI–LA ratio. In order to assess the sensitizing effect of
siRNA for a drug, doxorubicin (Sigma-Aldrich) was added after
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48 h of siRNA treatment at 5µg/mL concentration. The MTT
[3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltetrazolium] assay was
performed after 72 h of treatment. The MTT (Sigma-Aldrich, St.
Louis, MO, USA) was added to the cells at 1 mg/mL final con-
centration in HBSS and the cells were incubated for 45 min at
37°C and 5% CO2. Soluble MTT is transformed into insoluble
formazan crystals during this time by the activity of mitochondr-
ial dehydrogenase enzymes, giving a measure of cellular activity
(Sumantran, 2011). Dimethyl sulfoxide (DMSO) was added to
the well to dissolve the crystals of MTT dye and the optical density
was measured at 570 nm. The percentage viability was calculated as
follows: 100%× (absorbance of cells treated with an siRNA com-
plex/absorbance of untreated cells), where the activity of untreated
cells was taken as 100% cell growth.
VALIDATION OF IDENTIFIED TARGETS AND COMBINATIONAL siRNA
THERAPY
The CDC20, RAD51, and CHEK1 were identified as potential tar-
gets based on an initial screening of siRNAs against cell cycle
proteins. For validation, individual siRNAs against these cell cycle
proteins were obtained from Dharmacon (CDC20: Cat. No. D-
003225-10; RAD51: Cat. No. D-003530-02, and; Cat. No. CHEK1:
D-003255-06) and delivered to cells at 20 and 40 nM of siRNA
concentrations and 1:2, 1:4, and 1:8 siRNA:carrier ratios (in tripli-
cate). Another well-studied cell cycle protein, KSP (siRNA against
KSP: Cat. No. AM16706, Life Technologies) and a scrambled
siRNA (Cat. No. AM4635, Life Technologies) was included in the
validation study. The siRNAs were evaluated in MDA-MB-435,
MDA-MB-231, and MCF7 cells by using PEI–LA and PEI–CA as
indicated in Figure legends (Figures S2 and S3 in Supplemen-
tary Material). The combinational siRNA therapy was performed
using 20 nM of each CDC20, RAD51, CHEK1, KSP, and scram-
bled siRNA with the final siRNA concentration of 40 nM. The
siRNA to PEI–LA ratio was 1:2 in MDA-MB-435WT and 1:8 in
MDA-MB-435R cells at 40 nM of combinational siRNA. The MTT
assay was performed after 72 h of combinational treatment as indi-
cated above. The sensitizing effect of siRNA for doxorubicin was
determined using MDA-MB-435R cells at 20, 40, and 60 nM con-
centrations of siRNA with 1:2, 1:4, and 1:8 siRNA: PEI–LA ratios.
Doxorubicin (5µg/mL) was added to cells after 48 h of treatment
with siRNAs and inhibition of cell growth was assessed by the MTT
after 72 h of incubation.
QUANTIFICATION OF TRANSCRIPTS BY DROPLET DIGITAL PCR
The MDA-MB-435WT were seeded in six-well plates, and trans-
fected with siRNA complexes at 40 nM (1:2 siRNA:PEI–LA ratios).
Total RNA was isolated from MDA-MB-435WT after 24 and
48 h of treatment using TRIzol (Invitrogen). Two microgram
of total RNA was converted into cDNA using M-MLV reverse
transcriptase (Invitrogen) according to manufacturer’s instruc-
tion. The droplet digital PCR (ddPCR) was performed using
10 ng of each cDNA sample and ddPCR supermix for probes
by employing QX100 ddPCR system (Bio-Rad, Hercules, CA,
USA). The PrimeTime qPCR assays for CDC20 (Assay ID,
Hs.PT.58.41063796), RAD51 (Assay ID, Hs.PT.58.38809475), and
CHEK1 (Assay ID, Hs.PT.58.3518318) were ordered from IDT
(Coralville, IA, USA), while TaqMan gene expression assays for
KSP (Assay ID, Hs00189698_m1) and a reference gene, β-actin
(Assay ID, Hs01060665_g1) were purchased from Life Technolo-
gies. The ddPCR conditions comprised of an initial denaturation
for 10 min at 95°C followed by 45 cycles of denaturation for 30 s at
94°C and annealing for 1 min at 60°C, and the final extension for
10 min at 98°C. Template DNA was omitted from the ddPCR reac-
tion as a no template control (NTC) and the results of ddPCR were
analyzed using the QuantaSoft Software (Bio-Rad). The absolute
copy number of targeted gene was divided by the absolute copy
number of a reference gene β-actin and presented as percentage
based on untreated cells (100%).
TARGETING CELL CYCLE PROTEINS WITH DsiRNA
The DsiRNA, having displayed superior efficacy (i.e., sub-nM
concentrations) in previous studies (Snead et al., 2013), was
also explored to confirm the validity of chosen targets and
improve therapeutic efficacy with our carriers. Three DsiRNAs
targeting different locations of the mRNA transcript for CDC20,
RAD51, and CHEK1 were obtained from IDT, namely CDC20-1
(Cat. No. HSC.RNAi.N001255.12.1), CDC20-2 (Cat. No. HSC.
RNAi.N001255.12.2), CDC20-3 (Cat. No. HSC.RNAi.N001255.
12.3), RAD51-1 (Cat. No. HSC.RNAi.N001164269.12.1), RAD51-
2 (Cat. No. HSC.RNAi.N001164269.12.2), RAD51-3 (Cat. No.
HSC.RNAi.N001164269.12.3), CHEK1-1 (Cat. No. HSC.RNAi.N0
01114121.12.1),CHEK1-2 (Cat. No. HSC.RNAi.N001114121.12.2),
and CHEK1-3 (Cat. No. HSC.RNAi.N001114121.12.3) with
scrambled DsiRNA (Cat. No. DS NC1). The MDA-MB-435WT
and MDA-MB-435R cells were transfected with 20 and 40 nM of
DsiRNAs at 1:2, 1:4, and 1:8 DsiRNA:PEI–LA ratios. The sen-
sitizing effect of DsiRNAs for doxorubicin was determined in
MDA-MB-435R with the same DsiRNA concentrations by adding
doxorubicin (5µg/mL) after 48 h of DsiRNA treatment. The MTT
assay was performed after 72 h of DsiRNA treatment (24 h of dox-
orubicin treatment). The inhibition of cell growth by DsiRNAs
against these cell cycle protein targets were additionally deter-
mined in MDA-MB-231WT and MCF7 cells at 40 and 60 nM of
DsiRNA using various ratios of DsiRNA:PEI–LA (Figure S4 in
Supplementary Material).
ANIMAL STUDY
All experimental protocols using animals were approved by the
Animal Care and Use Committee: Health Sciences at the Univer-
sity of Alberta in accordance with the directions of the Canadian
Council on Animal Care. The athymic NCRNU nude mice (4–
6 weeks old male) to be used as a xenograft model were obtained
from Taconic Biosciences, Inc. (Hudson, NY, USA). Approxi-
mately three million MDA-MB-435WT cells were injected sub-
cutaneously into the right flank of the mice, and tumor growth
was monitored every 3 days. When the tumor volume reached
60–100 mm3 [measured by external calibers as indicated in Ali-
abadi et al. (2013b)], mice were put on the study by injecting
DsiRNA and polymer complexes subcutaneously in the vicinity
of the tumors. The mice were treated by 2µg of DsiRNA/mouse
(scrambled or CDC20-1) with 1:8 DsiRNA:PEI–LA ratio. All mice
were divided into two groups. First group of mice received weekly
injections of scrambled DsiRNA and CDC20-1 DsiRNA (n= 7 in
each study group) for 3 weeks. The second group of mice received
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the same siRNA treatment, but at bi-weekly injection intervals
(n= 7 in each study group). The subsequent tumor volumes were
measured twice a week with 3- and 4-day intervals. Any mouse
with large tumor volume (>1500 mm3), necrotic spot on tumor,
or excessive (>20%) weight loss was euthanized before the end-
time point of the study for humane considerations and excluded
from the entire study. Relative tumor volumes were calculated by
normalizing the tumor volumes at different time points with the
initial tumor volume (i.e., at the time a mouse is included in the
study; taken at 100% initially).
STATISTICAL ANALYSIS
All results were presented as mean± SD and analyzed by unpaired
Student’s t -test. The significance (p< 0.05) was typically deter-
mined by comparing specific siRNA-treated groups to that of
scrambled siRNA-treated groups. The significantly different treat-
ment groups are indicated with an asterisk (*) in Figures, with
reference groups indicated in the Legend.
RESULTS
INITIAL SCREENING OF CARRIERS
We previously reported successful delivery of siRNA for specific
targets in breast cancer cells using low molecular weight PEI-based
polymers (Aliabadi et al., 2011, 2013a,b; Montazeri Aliabadi et al.,
2011). As the efficacy of polymers and designed siRNAs was dif-
ferent for each targeted protein, we screened several polymers to
identify effective carrier for cell cycle proteins. We screened the
PEIs substituted with LA, CA, and αLA and used siRNA against
KSP in MDA-MB-435WT cells for this purpose. All chosen poly-
mers were effective for the delivery of KSP siRNA at 1:2 and 1:4
siRNA:polymer ratios employed (Figure 1). The effectiveness of
commercial carriers HiperFect and TurboFect was not evident
under similar conditions. Among the polymers, PEI–LA was cho-
sen for further studies since: (i) this polymer was equivalent in
potency to other polymers, and (ii) it was previously used with
other targets and in animal models with success (Aliabadi et al.,
2013b).
CELLULAR UPTAKE OF siRNA
The cellular uptake of FAM-labeled scrambled siRNA was per-
formed by flow cytometry to determine the efficiency of PEI–
LA to deliver siRNA in MDA-MB-435WT cells (Figure 2A).
An equivalent mean fluorescence and FAM-positive cell popu-
lation was observed between non-treated cell and cells exposed
to non-labeled siRNA (data not shown), indicating no cellu-
lar auto-fluorescence as a result of siRNA delivery. The siRNA
uptake (mean fluorescence) and FAM-labeled siRNA positive cells
were dependent on siRNA:PEI–LA ratios, and they were both
higher at 40 nM siRNA as compared to 20 nM siRNA concentra-
tion, as expected (Figure 2A). A significant difference was found
in FAM-labeled siRNA positive cells between 1:4 and 1:8 ratios
at 40 nM despite a similar mean fluorescence, suggesting that
a higher fraction of MDA-MB-435WT cells were transfected at
1:8 ratio. In order to quantify the number of siRNA–polymer
complexes per cell, confocal microscopy was employed and the
number of particles was calculated in each cell after taking image
by z-stacking (Figure 2B). Non-labeled siRNA was delivered in
FIGURE 1 | Screening of polymeric carriers in MDA-MB-435WT cells at
1:2 (A) and 1:4 (B) siRNA to carrier ratios with 20nM of scrambled
siRNA (control; CsiRNA) and KSP siRNA. Polyethylenimines (PEI)
substituted with linoleic acid (LA), caprylic acid (CA), and α-linoleic acid
(αLA) were used in the initial screen along with two commercially available
carriers.
MDA-MB-435WT (Figure 2Bi) as a control to observe any auto-
fluorescent particles; no fluorescent particles were found, which
confirmed a lack of auto-fluorescence in confocal microscopy as
well. The amount of siRNA–polymer complexes per cell was signif-
icantly different between 1:2 (Figure 2Bii) and 1:8 (Figure 2Biii)
siRNA:polymer ratios (Figure 2C). Both flow cytometry and con-
focal microscopy indicated a better delivery by PEI–LA at higher
ratio of siRNA:PEI–LA. A similar uptake study using flow cytom-
etry and confocal microscopy was additionally performed with
MCF7 cells (Figure S1 in Supplementary Material) and the results
again indicated a better delivery with a higher siRNA:PEI-LA ratio.
SCREENING OF CELL CYCLE PROTEINS
A screening of 169 siRNAs against cell cycle proteins was per-
formed using PEI–LA for delivery. The outcome was based on
inhibition of cell growth as assessed by the MTT assay (Figure 3A).
The growth inhibition was more significant in MDA-MB-435R
cells (up to >50% of control) compared to MDA-MB-231R cells
(typically<25% of control). Based on the response of MDA-MB-
435R cells, cell division cycle protein 20 (CDC20), the recombinase
RAD51, and the serine–threonine protein kinase CHEK1 were
identified as potential targets as >50% inhibition of cell growth
was achieved by the treatment of siRNA alone for these targets
(Figure 3A). In a subsequent study, doxorubicin was added to the
cells after 48 h of siRNA addition to determine whether siRNA
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FIGURE 2 | (A) Uptake of FAM-labeled siRNA complexes at 20 and
40 nM siRNA using 1:2, 1:4, and 1:8 siRNA:PEI–LA ratios. The
MDA-MB-435WT cells were incubated with the complexes for 24 h and
recovered for flow cytometry analysis. The results were summarized as
mean FAM-siRNA per cell (top) and FAM-siRNA positive cell population
(bottom). (B) Confocal microscopy to determine the uptake of
FAM-labeled siRNA complexes at 40 nM siRNA with 1:2 (ii) and 1:8 (iii)
siRNA:PEI–LA ratios after 24 h treatment. Purple, red, and green colors
represent nuclei, cytoplasm, and siRNA complexes, respectively.
Non-labeled scrambled siRNA was transfected as a control in
MDA-MB-435WT (i). (C)The number of visible complexes per cell (as
quantitated from confocal microscopy images) at 1:2 and 1:8
siRNA:PEI–LA ratios. The uptake was significantly different between 1:2
and 1:8 ratios (*p<0.05).
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FIGURE 3 | (A) Screening of the library of siRNAs against cell cycle
proteins using MDA-MB-231R and MDA-MB-435R cells. The identified cell
cycle proteins, CDC20, RAD51, and CHEK1 are indicated with the positive
control, PLK1. A specific siRNA against PLK1 (Polo-like kinase 1) was
provided with the cell cycle proteins; it was meant to assure the functioning
of siRNA delivery and was not pursued in this study. (B,C)The results of
siRNA treatment alone and siRNA/doxorubicin combinational treatment in
MDA-MB-231R (B) and MDA-MB-435R (C). (D)The difference in cell
growth between siRNA treatment alone and the combinational treatment.
Inhibition of cell growth in all cases was expressed as a percentage of
control (POC), which was calculated as a percentage of cell growth (from
MTT Assay) for scrambled siRNA-treated cells.
treatment resulted in sensitizing the cells to doxorubicin. The cell
growth of MDA-MB-231R was>70% after dual therapy of siRNA
and doxorubicin, except silencing of cyclin D3 (62%; Figure 3B).
The MDA-MB-435R cells were more responsive to siRNA therapy,
but the sensitizing effect of doxorubicin was not immediately clear
in these cells (Figure 3C). The difference in cell growth between
siRNA treatment alone and the dual therapy of siRNA/doxorubicin
is presented in Figure 3D. The difference in cell growth was
10–25% for many cell cycle proteins in MDA-MB-231R, except
homeodomain interacting protein kinase 2 (HIPK2, 46%), which
indicates a sensitizing effect for doxorubicin. However, the cell
growth of MDA-MB-231R after siRNA/doxorubicin therapy was
again >75% (Figure 3B), which was equivalent to siRNA alone.
VALIDATION AND FURTHER EVALUATION OF IDENTIFIED TARGETS
The individually prepared siRNAs against the selected cell cycle
proteins were used to determine the effectiveness of siRNA ther-
apy. Different siRNA concentrations and siRNA:PEI–LA ratios
were explored for this purpose. The inhibition of cell growth was
77 and 62% by delivering KSP siRNA to MDA-MB-435WT cells
at 20 nM (1:8) and 40 nM (1:2) siRNA compared to scrambled
siRNA using PEI-LA, respectively (Figures 4A,B). However, 1:4
and 1:8 siRNA:polymer ratios at 40 nM siRNA were found more
toxic based on the inhibition of cell growth of scrambled siRNA
(Figure 4B). Significant decrease in cell growth was observed
with 20 and 40 nM CHEK1 siRNA at 1:8 and 1:2 ratios com-
pared to scrambled siRNA, respectively, while cell growth was not
significantly decreased with CDC20 and RAD51 siRNA in MDA-
MB-435WT cells (Figures 4A,B). This study was repeated with
PEI–CA as the delivery agent and the obtained results were similar
(Figures 4C,D); a significant inhibition of cell growth was found
upon KSP and CHEK1 siRNA treatment at 40 nM siRNA concen-
tration. Consistent with the library screens, the siRNA treatment
was not effective in MDA-MB-231WT and MDA-MB-231R cells
at 54 nM siRNA using PEI–LA and PEI–CA at 1:2, 1:4, and 1:8
siRNA:polymer ratios (Figures S2 and S3 in Supplementary Mate-
rial). Similarly, inhibition of cell growth was not significant by
delivering these siRNAs to MCF7 cells using PEI-LA (40 and
60 nM siRNA) and PEI–CA (20 and 40 nM siRNA) at 1:2, 1:4, and
1:8 siRNA:polymer ratios (Figures S2 and S3 in Supplementary
Material).
We next explored dual delivery of siRNAs with the expectation
that if two essential cell cycle proteins are down-regulated simul-
taneously, cell cycle could be disrupted more significantly with
a more pronounced treatment effect. The combinational siRNA
therapy was performed using MDA-MB-435WT and MDA-MB-
435R cells with 40 nM total siRNA concentration (Figure 5). KSP
siRNA, on its own, was highly effective to achieve significant cell
death compared to scrambled siRNA. However, cell growth was
not drastically decreased using KSP siRNA when co-delivered with
CDC20, RAD51, and CHEK1 siRNAs compared to KSP siRNA
delivery alone. Similar results were observed with the combi-
nations of CDC20, RAD51, and CHEK1 siRNAs; (i) combining
CDC20 with KSP siRNA did not lead to any more inhibition of
cell growth with either siRNAs alone, (ii) a combination of RAD51
and CDC20 siRNAs led to a greater inhibition of cell growth
than RAD51 siRNA alone, but not CDC20 siRNA alone, and (iii)
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FIGURE 4 |Validation of KSP, CDC20, RAD51, and CHEK1 in
MDA-MB-435WT cells at 20nM (A,C) and 40nM (B,D) siRNA
concentrations. The results from PEI–LA were summarized in
(A,B) (siRNA:polymer ratios of 1:2, 1:4, and 1:8) while the results from
PEI–CA were summarized in (C,D) (siRNA:polymer ratios of 1:2 and 1:4).
Scrambled siRNA (CsiRNA) was used as a control. Significant (*p<0.05)
decreases in the cell growth were observed in specific siRNA-treated group
compared to CsiRNA.
CHEK1 siRNA combinations with RAD51 and CDC20 siRNA did
not lead to greater inhibition of cell growth than CHEK1 siRNA
alone. Taking together, these results indicated no synergistic effect
with combinational siRNA therapy.
We next explored the effect of siRNA delivery on the doxoru-
bicin response of the cells, with the purpose of assessing whether
silencing the chosen targets could sensitize the cells to doxoru-
bicin treatment (i.e., further inhibit cell growth as compared
to doxorubicin treatment alone). A range of siRNA doses was
employed (20, 40, and 60 nM) as well as siRNA:carrier ratios (1:2,
1:4, and 1:8) for a full silencing effect. The MDA-MB-435R cells
were subsequently exposed to doxorubicin after 48 h of siRNA
treatment targeting the cell cycle proteins. No significant effect
of the siRNA treatment was observed at 20 nM siRNA, result-
ing in no sensitizing effect of doxorubicin in MDA-MB-435R
cells (Figures 6A,D). KSP siRNA was the most effective siRNA
at 40 nM with 1:8 siRNA:polymer ratio compared to CDC20,
RAD51, and CHEK1 siRNAs (Figure 6B). However, the sensitizing
effect on doxorubicin was again not observed in the combina-
tional therapy of siRNA (40 nM) and doxorubicin (Figure 6E).
Similarly, no sensitizing effect of doxorubicin was observed at
60 nM siRNA concentrations with the drug treatment compared
to no drug treated group at the same siRNA concentration
(Figures 6C,F).
DOWN-REGULATION OF TARGETED PROTEIN TRANSCRIPTS
The down-regulation in the levels of mRNA transcripts of tar-
geted proteins was analyzed with ddPCR in MDA-MB-435WT
by determining absolute transcripts quantities. The levels of KSP
transcripts were not significantly decreased in KSP siRNA-treated
cells after 24 h of siRNA treatment (Figure 7A); however, a signif-
icant decrease was obtained after 48 h of treatment (Figure 7B).
The amount of KSP transcripts in treated cells was ~60%, indi-
cating that a relatively small change in levels of KSP transcripts
inhibited cell growth drastically as KSP siRNA decreased the cell
growth>70% (Figure 4). The CDC20 and RAD51 siRNAs silenced
their mRNA targets more effectively compared to other cell cycle
proteins as only ~30% transcripts were found in the siRNA-
treated cells (Figure 7B). However, MDA-MB-435WT cells had
escaped the effect of CDC20 and RAD51 siRNA treatment and
survived with low copy numbers of CDC20 and RAD51 tran-
scripts (Figure 4). A significant difference in the levels of CHEK1
transcripts was also found between scrambled siRNA and CHEK1
siRNA-treated cells after 48 h (Figure 7B). It was interesting to
note that the levels of gene transcripts were variable among the
chosen targets after the control siRNA treatment; while some tran-
scripts were not affected (e.g., RAD51 at 24 h and CHEK1 at 48 h),
others displayed as much as ~40% reduction in transcript lev-
els as compared to untreated control cells (e.g., CDC20 at 24 h
and RAD51 at 48 h). The reason(s) for such a variation is not
known.
DsiRNA DELIVERY AGAINST CELL CYCLE PROTEINS
To explore the effectiveness of alternative RNAi reagents, three
DsiRNAs targeting different locations in mRNA was delivered
against CDC20, RAD51, and CHEK1 in MDA-MB-435WT and
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FIGURE 5 | Combinations of siRNA (20+20nM) treatments among
KSP, CDC20, RAD51, and CHEK1 siRNA in MDA-MB-435WT
(A) with siRNA:PEI-LA ratio of 1:2 and MDA-MB-435R (B) with
siRNA:PEI–LA ratio of 1:8. Scrambled siRNA (CsiRNA) was used as a
control on its own as well as in combination with other siRNAs. The SD (not
shown) was <5% for all groups.
MDA-MB-435R using PEI–LA. The siRNA concentrations were 20
and 40 nM and 1:2, 1:4, and 1:8 DsiRNA:polymer ratios were used
(Figure 8). The CDC20-1 DsiRNA was the most effective among
three DsiRNAs as the inhibition of cell growth was >80% at 20
and 40 nM concentrations in MDA-MB-435WT. The CDC20-2
and CDC20-3 DsiRNAs were not effective in MDA-MB-435WT
cells. The DsiRNA:PEI–LA ratios 1:4 and 1:8 at 40 nM were toxic
as only ~30% cell growth was found in scramble DsiRNA treated
cells (Figure 8B). Similarly, a significant decrease in cell growth was
observed by delivering CDC20-1 DsiRNA to MDA-MB-435R, and
CDC20-2 and CDC20-3 DsiRNAs were again not as effective as
CDC20-1 in this cell at 20 nM (Figure 8C) and 40 nM (Figure 8D).
Again, CDC20-1 inhibited the growth of MDA-MB-231WT cells
significantly, and CDC20-2 and CDC20-3 were unable to decrease
the cell growth (Figure S4 in Supplementary Material). All three
DsiRNAs against CDC20 were effective in MCF7 cells at 40 and
60 nM DsiRNAs (Figure S4 in Supplementary Material). How-
ever, the DsiRNA:polymer ratio 1:4 inhibited more MCF7 growth
compared to 1:2 and 1:8 ratios, which was different from MDA-
MB-435 cells, where the higher ratios inhibited cell growth more
effectively.
The DsiRNAs against RAD51 were not as effective as CDC20-1
(Figure 8). RAD51-1 inhibited the MDA-MB-435WT cell growth
~20% compared to scrambled DsiRNA at 20 nM with 1:4 and 1:8
DsiRNA to PEI–LA ratios. No drastic decrease in the cell growth
was detected by delivering RAD51-2 and RAD51-3 to MDA-MB-
435WT cells at 20 and 40 nM. The significant decrease in the MDA-
MB-435R cell growth was only observed at 40 nM of DsiRNA at
1:8 ratio with all three DsiRNAs (Figure 8D). RAD51 DsiRNAs
were not effective in MDA-MB-231WT cells (Figure S4 in Supple-
mentary Material). However, MCF7 cells were more sensitive to
all three RAD51 DsiRNAs, which inhibited cell growth drastically
at 60 nM of DsiRNA (Figure S4 in Supplementary Material).
All CHEK1 DsiRNAs decreased the MDA-MB-435WT cell
growth significantly compared to scrambled DsiRNA at 20 nM
with various ratios (Figure 8A). However, 1:8 DsiRNA:PEI-LA
ratio at 20 nM was the most effective ratio in MDA-MB-435WT as
~40% cell growth was inhibited. Since the higher ratios at 40 nM
of DsiRNA were toxic, the inhibition of cell growth by CHEK1
DsiRNAs alone was quite low at 40 nM (Figure 8B). Only the
higher CHEK1 DsiRNA:polymer ratios inhibited the MDA-MB-
435R cells significantly at 20 and 40 nM of DsiRNAs (Figure 8D).
The CHEK1 DsiRNAs were not effective in MDA-MB-231WT cells
(Figure S4 in Supplementary Material). CHEK1-1 decreased the
MCF7 cell growth drastically at 40 and 60 nM of DsiRNA at differ-
ent ratios. CHEK1-2 and CHEK1-3 DsiRNAs failed to inhibit the
cell growth drastically in MCF7 cells (Figure S4 in Supplementary
Material).
The sensitizing effect of DsiRNAs for doxorubicin was not
observed in MDA-MB-435R at 20 and 40 nM, as a similar inhi-
bition of cell growth was observed between DsiRNA/doxorubicin-
treated and DsiRNA treated cells (data not shown).
IN VIVO CDC20 DsiRNA THERAPY
Since the CDC20-1 DsiRNA led to >80% growth inhibition in
MDA-MB-435WT cells in vitro (more so than the CDC20 siRNA
from library screens), we further evaluated its efficacy in vivo by
injecting DsiRNA/PEI-LA complexes to breast cancer xenografts
weekly and bi-weekly subcutaneously in the vicinity of tumor.
In the weekly injection group, the initial growth of scrambled
and CDC20-1 DsiRNA treated tumor was similar (Figure 9A).
However, the growth of tumor was suppressed after the sec-
ond injection of CDC20-1 DsiRNA and a significant difference
compared to scrambled DsiRNA treated tumor was achieved on
day 14. Similarly, the third injection also decreased the growth
of CDC20-1 DsiRNA treated tumor significantly on day 17. In
the bi-weekly injection groups, the slower growth was evident
with CDC20-1 DsiRNA treated group from the beginning of the
study, where the differences between the CDC20-1 and scram-
bled DsiRNA were significant on day 7 and 14 (Figure 9B). The
tumor growth was retarded significantly after the second injection
of CDC20-1 DsiRNA on day 17 and the difference in growth rate
between scrambled and CDC20-1 DsiRNA treated tumor started
decreasing gradually thereafter.
DISCUSSION
The siRNA mediated RNAi has become a powerful tool for its
specificity and efficiency to knock-down targets that cannot be
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FIGURE 6 | Effect of siRNA on doxorubicin cytotoxicity in MDA-MB-435R cells. The cells were first treated with siRNA at 20 nM (A,D), 40 nM (B,E), and
60 nM (C,F) with 1:2, 1:4, and 1:8 siRNA:PEI-LA ratios, followed by treatment with buffer [(A–C); −DOX] or doxorubicin [(D–F); +DOX]. Scrambled siRNA
(CsiRNA) was used as a control.
readily down-regulated by conventional chemotherapy (McManus
and Sharp, 2002; Kim and Rossi, 2007). However, an efficient deliv-
ery system has to be developed for a functional siRNA effect (Pecot
et al., 2011; Bora et al., 2012). Here, we report polymeric delivery
systems, PEI-LA and PEI-CA, for siRNA therapy against cell cycle
proteins in breast cancer cells. Lipid moieties that have been used
to substitute amines of PEI were speculated to increase the inter-
action of anionic cell membrane with complexes (nanoparticles)
of siRNA formed with cationic polymers, which in turn facilitate
the entry of anionic siRNA into the cell. The optimal ratio of
polymer to siRNA for each cell-line needs to be determined as a
balance between the cytotoxicity of the polymer (lower cytotoxic-
ity at lower ratios) and effective siRNA delivery (increased siRNA
delivery at higher ratios). The current study mostly utilized in vitro
cell models since, at the onset of study, little was known about the
feasibility of silencing the newly explored targets to obtain a ther-
apeutic effect. Detailed studies on dose–response relationships,
relative potency of silencing each identified target, and details of
siRNA delivery system (efficiency and undesired cytotoxicity) were
thoroughly explored in vitro. With the critical insight generated in
this study, further in vivo studies are warranted to better explore
the potential of the identified targets.
The arrest of cell cycle by knocking out or inhibiting specific
proteins was explored previously by others (Schwartz and Shah,
2005; Satyanarayana and Kaldis, 2009). Our results (based on PCR
analysis and inhibition of cell growth) highlighted three specific
mediators, namely CDC20, RAD51, and CHEK1, as therapeu-
tic targets in breast cancer cells. Western blot analysis to assess
protein levels as a result of specific siRNA delivery would have
been additionally useful to better validate these targets, but the
inhibition of cell growth by specific siRNAs was considered a
strong indication for their importance and a practical end-point to
identify leads. The CDC20 activates the anaphase-promoting com-
plex (APC) in the cell cycle, which initiates chromatid separation
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FIGURE 7 | Digital droplet PCR (ddPCR) analysis in MDA-MB-435WT
cells after 24h (A) and 48h (B) of treatment with indicated siRNAs. The
percentage of quantity of transcripts was calculated based on the
transcripts level of untreated cells (100%). The significance (*) at p< 0.05
was calculated for specific siRNA-treated group based on CsiRNA.
and entrance into anaphase (Weinstein, 1997). RAD51 repairs
the DNA double-strand break during homologous recombination
(Galkin et al., 2006). CHEK1 has kinase activity and phospho-
rylates CDC25, an important phosphatase for entry of the cell
into mitosis (Chen et al., 2003). There are already a precedent
for the roles of unregulated CDC20, RAD51, and CHEK1 in can-
cer development and progression. CDC20 has been found to be
overexpressed in many cancer types (Takahashi et al., 1999; Kim
et al., 2005b; Iacomino et al., 2006; Ouellet et al., 2006; Kidokoro
et al., 2008), which may deregulate activation process of APC and
often result in multinucleation, premature anaphase promotion,
and mis-segregation of chromosomes, and leads to chromoso-
mal instability and defect in spindle assembly checkpoint response
(Mondal et al., 2007; Wang et al., 2013). Given the role of RAD51
in DNA double-strand break repair (Galkin et al., 2006), RAD51
up-regulation increases the number of recombination events that
may lead to defective DNA strands (Richardson et al., 2004). In
addition, spontaneous recombination frequency may increase in
mammalian cells because of overexpression of RAD51, which ulti-
mately provides resistance to chemotherapy (Vispé et al., 1998;
Klein, 2008). CHEK1, on the other hand, is an essential cell cycle
protein to maintain genomic stability. Syljuåsen et al. (2005) sug-
gested that CHEK1 is a required protein to avoid uncontrolled
increase in DNA replication, thereby protecting against DNA
breakage. Although this literature supported all three targets for
RNAi based cancer therapy, only a few studies attempted to silence
CDC20, RAD51, and CHEK1 expression by siRNA (Syljuåsen et al.,
2005; Taniguchi et al., 2008; Tsai et al., 2010). Commercial carri-
ers such as RNAiFect™ reagent (Qiagen), Lipofectamine™ 2000
and Oligofectamine™(Invitrogen) were used to deliver CDC20,
RAD51, and CHEK1 siRNA, respectively, and these studies were
conducted in pancreatic, non-small-cell lung carcinoma (NSCLC),
and osteosarcoma cell-lines. The breast cancer therapy investigated
here might be an additional indication for these targets in RNAi
therapy.
Our studies indicated that MDA-MB-435R cells were more
responsive to siRNA treatment as compared to MDA-MB-231R.
One possible reason might be that the polymeric carrier has not
delivered siRNAs effectively to MDA-MB-231R cells. We previ-
ously reported that MDA-MB-231R cells displayed lower uptake
compared to MDA-MB-435R cells under identical culture condi-
tions (Aliabadi et al., 2013b), so that lower quantitative delivery of
intracellular siRNA could be one of the reasons for lower efficacy
in these cells. Another possibility is that the targeted cell cycle pro-
teins may not be as crucial for the survival of MDA-MB-231R,
unlike the MDA-MB-435R cells, and the MDA-MB-231R cells
may have circumvented the effect of siRNA treatment by recruit-
ing alternative mediators. However, individually prepared siRNAs
against three cell cycle proteins showed lower efficacy in MDA-
MB-435WT (Figures 4 and 7) and MDA-MB-435R (Figure 6), and
these siRNAs were not effective at all in MDA-MB-231WT, MDA-
MB-231R, and MCF7 cells (Figures S2 and S3 in Supplementary
Material), which might be an indication of these siRNAs not being
efficiently incorporated into the RISC assembly. In order to address
this possibility, we determined the efficacy of DsiRNAs against the
three cell cycle proteins. DsiRNA (27 base pairs) interacts with the
dicer enzyme before its incorporation into RISC assembly, leading
to increased potency by engaging to the natural siRNA processing
pathway (Kim et al., 2005a). Three 27 bp DsiRNAs for each target
were not uniformly effective than the 21 bp siRNA used in this
study, but we are cognizant of the fact that different regions of
mRNA were targeted with each RNAi reagent and this might have
contributed to variation in their efficacy. However, the CDC20-1
DsiRNA was clearly the most effective among the tested reagents,
which led us to determine its efficacy in a xenograft model. The
CDC20-1 DsiRNA was able to decrease the tumor growth in both
weekly and bi-weekly injection groups. The retardation of tumor
growth with CDC20-1 DsiRNA was not as robust as other studies
in the literature. However, the DsiRNA dose used here was 2µg
(~0.08 mg/kg/day), which was quite low compared to 4–10µg of
siRNA used in intratumoral injections in previous studies and
some higher doses (up to 40µg of siRNA) used in other modes
of administrations (Behlke, 2006). We did not employ intratu-
moral injections since that might alter tumor growth patterns and
complicate the interpretation of tumor growth data. Moreover,
we reduced the number of injections in our study to weekly and
bi-weekly, leading to a large interval between the injections as 1–5-
day durations were frequently employed in previous in vivo studies
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FIGURE 8 | Inhibition of cell growth using DsiRNAs against
CDC20, RAD51, and CHEK1 at 20 and 40nM DsiRNA
concentrations with different DsiRNA:PEI–LA ratios in
MDA-MB-435WT (A,B) and MDA-MB-435R (C,D). For each target
proteins, three different DsiRNA isoforms were used. The
significance (*) at p< 0.05 was calculated for specific DsiRNA treated
group compared to scrambled DsiRNA (CsiRNA) at the equivalent
concentration/ratio used.
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FIGURE 9 | Effect of CDC20 DsiRNA treatment in vivo. Xenografts of
MDA-MB-435WT were established in nude mice, and were treated with a
scrambled DsiRNA (CsiRNA) and CDC20-1 DsiRNA. Relative tumor volume
for weekly injection [(A); n=6 and n=5 in CsiRNA and CDC20-1 groups,
respectively] and bi-weekly injection [(B); n=3 and n=4 in CsiRNA and
CDC20-1, respectively] groups, are summarized (only positive SDs are
shown for clarity). The time points that showed a significant decrease in the
volume of CDC20-1 DsiRNA treated tumors compared to CsiRNA treated
tumor are indicated with an asterisk (p< 0.05).
(Behlke, 2006). Even though the dose of DsiRNA and frequency
of injections were low, the CDC20-1 DsiRNA was effective to
slow down the growth of tumor compared to scrambled DsiRNA
(Figure 9). We must, however, note that no buffer injection group
was employed in the animal study, so that we could not evaluate if
the scrambled DsiRNA complexes had any effect on tumor growth
due to non-specific toxicity.
The resistance to the chemotherapy arises due to molecular
(protein) changes in cancer cells (Luqmani, 2005). If a protein
associated with drug resistance was to be down-regulated by
siRNA therapy, cells could be sensitized to chemotherapy. This
issue was explored in several experiments with cell cycle pro-
teins in this study, where the silencing of particular proteins
were first attempted to investigate subsequent drug (doxorubicin)
response. Since doxorubicin action involves DNA intercalation to
inhibit DNA replication and ultimately cell cycle arrest, we ini-
tially reasoned that protein controlling the cell cycle could be
altered in doxorubicin-treated cells, as observed in MCF7 cells
(AbuHammad and Zihlif, 2013). The drug-resistant MDA-MB-
231R and MDA-MB-435R cells were not sensitized to doxorubicin
after siRNA therapy (either as a single or dual siRNA delivery),
indicating that the targeted cell cycle proteins may not be con-
tributing to resistance against doxorubicin in breast cancer cells.
Our previous studies with siRNA delivery were able to sensitize
breast cancer cells by targeting anti-apoptotic proteins survivin
(Montazeri Aliabadi et al., 2011) and Mcl-1 (Aliabadi et al., 2013a),
so that this class of proteins (rather than cell cycle proteins)
might be more suitable to target for chemo-sensitization. However,
beyond chemo-sensitization, cell cycle proteins could serve as tar-
gets to inhibit metastasis, since delivering specific siRNAs against
survivin and cyclin B1 (with linear PEI) were found to be effective
to prevent lung metastasis in a mammary adenocarcinoma model
in mice (Bonnet et al., 2013).
Another cell cycle protein, KSP, has been investigated as a tar-
get for RNAi therapy and currently it is being evaluated at clinics
(Tabernero et al., 2013). As KSP is a microtubule-based motor
protein and plays a critical role during mitosis to separate cen-
trosome and to assemble bipolar spindle, knock-down of KSP
expression leads to cell cycle arrest, and ultimately to cell death.
KSP was another effective target with the described polymeric
delivery system. We previously observed that silencing multi-
ple targets by delivering multiple siRNAs simultaneously led to
improved therapeutic responses (Aliabadi et al., 2013a,b); how-
ever, this was not the case here when KSP was combined with
siRNAs targeting one of the cell cycle proteins. KSP on its own
seemed to be effective enough to eradicate >70% cells. KSP with
vascular endothelial growth factor (VEGF) siRNA is in clinical use
(Tabernero et al., 2013), so that other targets beyond the cell cycle
proteins might still be suitable for combinational therapy with
KSP siRNA. Lipid nanoparticles (LNP) are used to deliver KSP–
VEGF siRNAs intravenously, which form micelles around siRNA
to protect its extracellular degradation. The modified PEI used for
delivery of KSP siRNA here interacts electrostatically with siRNA
and might provide an alternative delivery system for this clinically
useful siRNA.
In conclusion, we report effective polymers derived from lipid-
substituted 2 kDa PEI to target proteins involved in cell cycle
regulation in breast cancer cells. No clear difference was evident
in our study whether a CA or LA modification of PEI was more
effective. The proteins CDC20, RAD51, and CHEK1 were identi-
fied as promising targets among the cell cycle proteins for non-viral
RNAi therapy. The specific type of RNAi reagent, siRNA (21 bp),
or DsiRNA (27 bp), was found to influence the efficacy of ther-
apy for individual targets, but more studies are needed to clarify
the exact reason for the differences. Although we expected the
siRNA therapy against cell cycle proteins to sensitize the cells with
chemotherapy, no such effect was evident when doxorubicin was
employed as a sensitizing drug. Nevertheless, a DsiRNA against
CDC20 was the most potent RNAi reagent in our hands, and it
also effectively slowed the growth of breast cancer xenografts in
an animal model. The present study highlighted the importance
of cell cycle protein targets in breast cancer therapy, and demon-
strated an effective delivery system for down-regulation of cell
cycle proteins.
ACKNOWLEDGMENTS
We thank Ms. Juliana Valencia-Serna for the technical assistance
in confocal microscopy. Manoj Parmar is a recipient of Dorothy
Frontiers in Bioengineering and Biotechnology | Biomaterials February 2015 | Volume 3 | Article 14 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parmar et al. siRNA delivery against cell cycle proteins
Whiteman Scholarship, Women and Children’s Health Research
Institute (WCHRI) Graduate Studentship Grant, and Alberta
Innovates-Health Solutions (AIHS) Graduate Studentship. This
study was supported by operating grants from Canadian Breast
Cancer Foundation (CBCF) and Natural Sciences and Engineering
Council of Canada (NSERC).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fbioe.2015.00014/
abstract
REFERENCES
AbuHammad, S., and Zihlif, M. (2013). Gene expression alterations in doxorubicin
resistant MCF7 breast cancer cell line. Genomics 101, 213–220. doi:10.1016/j.
ygeno.2012.11.009
Aliabadi, H. M., Landry, B., Bahadur, R. K., Neamnark, A., Suwantong, O., and
Uludag˘, H. (2011). Impact of lipid substitution on assembly and delivery of
siRNA by cationic polymers. Macromol. Biosci. 11, 662–672. doi:10.1002/mabi.
201000402
Aliabadi, H. M., Landry, B., Sun, C., Tang, T., and Uludag˘, H. (2012). Supramolecu-
lar assemblies in functional siRNA delivery: where do we stand? Biomaterials 33,
2546–2569. doi:10.1016/j.biomaterials.2011.11.079
Aliabadi, H. M., Mahdipoor, P., and Uludag˘, H. (2013a). Polymeric delivery of
siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induc-
tion in drug-resistant breast cancer cells. Cancer Gene Ther. 20, 169–177.
doi:10.1038/cgt.2013.8
Aliabadi, H. M., Maranchuk, R., Kucharski, C., Mahdipoor, P., Hugh, J., and Uludag˘,
H. (2013b). Effective response of doxorubicin-sensitive and -resistant breast
cancer cells to combinational siRNA therapy. J. Control. Release 172, 219–228.
doi:10.1016/j.jconrel.2013.08.012
Amarzguioui, M., and Rossi, J. J. (2008). Principles of dicer substrate (D-siRNA)
design and function. Methods Mol. Biol. 442, 3–10. doi:10.1007/978-1-59745-
191-8_1
Bahadur, K. C., Landry, B., Aliabadi, H. M., Lavasanifar, A., and Uludag˘, H. (2011).
Lipid substitution on low molecular weight (0.6-2.0 kDa) polyethylenimine leads
to a higher zeta potential of plasmid DNA and enhances transgene expression.
Acta Biomater. 7, 2209–2217. doi:10.1016/j.actbio.2011.01.027
Behlke, M. A. (2006). Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644–670.
doi:10.1016/j.ymthe.2006.01.001
Blangy, A., Lane, H. A., d’Hérin, P., Harper, M., Kress, M., and Nigg, E. A. (1995).
Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a
kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83,
1159–1169. doi:10.1016/0092-8674(95)90142-6
Bonnet, M. E., Gossart, J. B., Benoit, E., Messmer, M., Zounib, O., Moreau, V., et al.
(2013). Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor
metastasis inhibition. J. Control. Release 170, 183–190. doi:10.1016/j.jconrel.
2013.05.015
Bora, R. S., Gupta, D., Mukkur, T. K., and Saini, K. S. (2012). RNA interference
therapeutics for cancer: challenges and opportunities. Mol. Med. Rep. 6, 9–15.
doi:10.3892/mmr.2012.871
Chen, M. S., Ryan, C. E., and Piwnica-Worms, H. (2003). Chk1 kinase negatively
regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol.
Cell. Biol. 23, 7488–7497. doi:10.1128/MCB.23.21.7488-7497.2003
Cooper, G. M. (2000). The Cell: A Molecular Approach, 2nd Edn. Washington, DC:
ASM Press.
Dagenbach, E. M., and Endow, S. A. (2004). A new kinesin tree. J. Cell Sci. 117, 3–7.
doi:10.1242/jcs.00875
Galkin, V. E., Wu, Y., Zhang, X. P., Qian, X., He, Y., Yu, X., et al. (2006). The
Rad51/RadA N-terminal domain activates nucleoprotein filament ATPase activ-
ity. Structure 14, 983–992. doi:10.1016/j.str.2006.04.001
Gillet, J. P., and Gottesman, M. M. (2010). Mechanisms of multidrug resistance in
cancer. Methods Mol. Biol. 596, 47–76. doi:10.1007/978-1-60761-416-6_4
Haupenthal, J., Baehr, C., Kiermayer, S., Zeuzem, S., and Piiper, A. (2006). Inhibition
of RNAse A family enzymes prevents degradation and loss of silencing activity
of siRNAs in serum. Biochem. Pharmacol. 71, 702–710. doi:10.1016/j.bcp.2005.
11.015
Iacomino, G., Medici, M. C., Napoli, D., and Russo, G. L. (2006). Effects of histone
deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line. J. Cell.
Biochem. 99, 1122–1131. doi:10.1002/jcb.21014
Kidokoro, T., Tanikawa, C., Furukawa, Y., Katagiri, T., Nakamura, Y., and Matsuda,
K. (2008). CDC20, a potential cancer therapeutic target, is negatively regulated
by p53. Oncogene 27, 1562–1571. doi:10.1038/sj.onc.1210799
Kim, D. H., Behlke, M. A., Rose, S. D., Chang, M. S., Choi, S., and Rossi, J. J.
(2005a). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy.
Nat. Biotechnol. 23, 222–226. doi:10.1038/nbt1051
Kim, J. M., Sohn, H. Y., Yoon, S. Y., Oh, J. H., Yang, J. O., Kim, J. H., et al. (2005b).
Identification of gastric cancer-related genes using a cDNA microarray contain-
ing novel expressed sequence tags expressed in gastric cancer cells. Clin. Cancer
Res. 11, 473–482.
Kim, D. H., and Rossi, J. J. (2007). Strategies for silencing human disease using RNA
interference. Nat. Rev. Genet. 8, 173–184. doi:10.1038/nrg2006
Klein, H. L. (2008). The consequences of Rad51 overexpression for normal and
tumor cells. DNA Repair 7, 686–693. doi:10.1016/j.dnarep.2007.12.008
Luqmani,Y. A. (2005). Mechanisms of drug resistance in cancer chemotherapy. Med.
Princ. Pract. 14, 35–48. doi:10.1159/000086183
Malumbres, M., and Carnero, A. (2003). Cell cycle deregulation: a common motif
in cancer. Prog. Cell Cycle Res. 5, 5–18.
Marra, E., Palombo, F., Ciliberto, G., and Aurisicchio, L. (2013). Kinesin spin-
dle protein siRNA slows tumor progression. J. Cell. Physiol. 228, 58–64.
doi:10.1002/jcp.24103
McManus, M. T., and Sharp, P. A. (2002). Gene silencing in mammals by small
interfering RNAs. Nat. Rev. Genet. 3, 737–747. doi:10.1038/nrg908
Mondal, G., Sengupta, S., Panda, C. K., Gollin, S. M., Saunders, W. S., and Roy-
choudhury, S. (2007). Overexpression of Cdc20 leads to impairment of the spin-
dle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28,
81–92. doi:10.1093/carcin/bgl100
Montazeri Aliabadi, H., Landry, B., Mahdipoor, P., and Uludag˘, H. (2011). Induc-
tion of apoptosis by survivin silencing through siRNA delivery in a human breast
cancer cell line. Mol. Pharm. 8, 1821–1830. doi:10.1021/mp200176v
Ouellet, V., Guyot, M. C., Le Page, C., Filali-Mouhim, A., Lussier, C., Tonin, P. N.,
et al. (2006). Tissue array analysis of expression microarray candidates identifies
markers associated with tumor grade and outcome in serous epithelial ovarian
cancer. Int. J. Cancer 119, 599–607. doi:10.1002/ijc.21902
Parmar, M. B., and Uludag˘, H. (2015). “Targeting cyclins and cyclin-dependent
kinases involved in cell cycle regulation by RNAi as a potential cancer therapy,”
in Nanomedicines: Design, Delivery and Detection, ed. M. Braddock (London:
Royal Society of Chemistry) (in press).
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., and Sood,A. K. (2011).
RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer
11, 59–67. doi:10.1038/nrc2966
Remant Bahadur, K. C., and Uludag˘, H. (2011). A comparative evaluation of
disulfide-linked and hydrophobically-modified PEI for plasmid delivery. J. Bio-
mater. Sci. Polym. Ed. 22, 873–892. doi:10.1163/092050610X496297
Richardson, C., Stark, J. M., Ommundsen, M., and Jasin, M. (2004). Rad51 overex-
pression promotes alternative double-strand break repair pathways and genome
instability. Oncogene 23, 546–553. doi:10.1038/sj.onc.1207098
Sandhu, C., and Slingerland, J. (2000). Deregulation of the cell cycle in cancer. Cancer
Detect. Prev. 24, 107–118.
Satyanarayana, A., and Kaldis, P. (2009). Mammalian cell-cycle regulation: several
Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28,
2925–2939. doi:10.1038/onc.2009.170
Schwartz, G. K., and Shah, M. A. (2005). Targeting the cell cycle: a new
approach to cancer therapy. J. Clin. Oncol. 23, 9408–9421. doi:10.1200/JCO.2005.
18.341
Snead, N. M., Wu, X., Li, A., Cui, Q., Sakurai, K., Burnett, J. C., et al. (2013).
Molecular basis for improved gene silencing by Dicer substrate interfering
RNA compared with other siRNA variants. Nucleic Acids Res. 41, 6209–6221.
doi:10.1093/nar/gkt200
Sumantran, V. N. (2011). Cellular chemosensitivity assays: an overview. Methods
Mol. Biol. 731, 219–236. doi:10.1007/978-1-61779-080-5_19
Syljuåsen, R. G., Sørensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson,
F., et al. (2005). Inhibition of human Chk1 causes increased initiation of DNA
replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol.
25, 3553–3562. doi:10.1128/MCB.25.9.3553-3562.2005
www.frontiersin.org February 2015 | Volume 3 | Article 14 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parmar et al. siRNA delivery against cell cycle proteins
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss,
G. J., et al. (2013). First-in-humans trial of an RNA interference therapeutic
targeting VEGF and KSP in cancer patients with liver involvement. Cancer Dis-
cov. 3, 406–417. doi:10.1158/2159-8290.CD-12-0429
Takahashi, T., Haruki, N., Nomoto, S., Masuda, A., Saji, S., Osada, H., et al. (1999).
Identification of frequent impairment of the mitotic checkpoint and molecular
analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung
cancers. Oncogene 18, 4295–4300. doi:10.1038/sj.onc.1202807
Taniguchi, K., Momiyama, N., Ueda, M., Matsuyama, R., Mori, R., Fujii, Y., et al.
(2008). Targeting of CDC20 via small interfering RNA causes enhancement of
the cytotoxicity of chemoradiation. Anticancer Res. 28, 1559–1563.
Tsai, M. S., Kuo, Y. H., Chiu, Y. F., Su, Y. C., and Lin, Y. W. (2010). Down-
regulation of Rad51 expression overcomes drug resistance to gemcitabine in
human non-small-cell lung cancer cells. J. Pharmacol. Exp. Ther. 335, 830–840.
doi:10.1124/jpet.110.173146
Vermeulen, K., Van Bockstaele, D. R., and Berneman, Z. N. (2003). The cell cycle: a
review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif.
36, 131–149. doi:10.1046/j.1365-2184.2003.00266.x
Vispé, S., Cazaux, C., Lesca, C., and Defais, M. (1998). Overexpression of Rad51
protein stimulates homologous recombination and increases resistance of mam-
malian cells to ionizing radiation. Nucleic Acids Res. 26, 2859–2864. doi:10.1093/
nar/26.12.2859
Wang, Z., Wan, L., Zhong, J., Inuzuka, H., Liu, P., Sarkar, F. H., et al. (2013). Cdc20:
a potential novel therapeutic target for cancer treatment. Curr. Pharm. Des. 19,
3210–3214. doi:10.2174/1381612811319180005
Weinstein, J. (1997). Cell cycle-regulated expression, phosphorylation, and degra-
dation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1. J. Biol. Chem.
272, 28501–28511. doi:10.1074/jbc.272.45.28501
Wilson, R. C., and Doudna, J. A. (2013). Molecular mechanisms of RNA interference.
Annu. Rev. Biophys. 42, 217–239. doi:10.1146/annurev-biophys-083012-130404
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 11 November 2014; accepted: 26 January 2015; published online: 16 February
2015.
Citation: Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R,
Hugh JC and Uludag˘ H (2015) Targeting cell cycle proteins in breast cancer cells with
siRNA by using lipid-substituted polyethylenimines. Front. Bioeng. Biotechnol. 3:14.
doi: 10.3389/fbioe.2015.00014
This article was submitted to Biomaterials, a section of the journal Frontiers in
Bioengineering and Biotechnology.
Copyright © 2015 Parmar, Aliabadi, Mahdipoor, Kucharski, Maranchuk, Hugh and
Uludag˘. This is an open-access article distributed under the terms of the Creative Com-
mons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Bioengineering and Biotechnology | Biomaterials February 2015 | Volume 3 | Article 14 | 14
